← All trials
NCT05317676
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 30, 2022
- Primary completion
- Apr 30, 2023
- Completion date
- Jun 30, 2023
- First posted
- Apr 8, 2022
- Last posted
- Apr 8, 2022
- Enrollment
- 50
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of California, IrvineLead sponsor
- University of California, IrvineReponsible party - principal investigator
- GencorCollaborator
- University of California, IrvineSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.